Table 2.
Comparison of oncologic variables of patients between the ELAPE group and APE group
| ELAPE (n = 71) | APE (n = 50) | P value | |
|---|---|---|---|
| (y)pT stage [n (%)] | 0.836a | ||
| pT1–2 | 24 (33.8) | 16 (32.0) | |
| pT3–4 | 47 (66.2) | 34 (68.0) | |
| ypT stage [n (%)] | 1.000a | ||
| ypT1–2 | 12 (37.5) | 5 (38.5) | |
| ypT3–4 | 20 (62.5) | 8 (61.5) | |
| (y)pN stage [n (%)] | 0.213a | ||
| pN0 | 49 (69.0) | 29 (58.0) | |
| pN1–2 | 22 (31.0) | 21 (42.0) | |
| ypN stage [n (%)] | 1.000a | ||
| ypN0 | 23 (71.9) | 9 (69.2) | |
| ypN1–2 | 9 (28.1) | 4 (30.8) | |
| (y)pTNM stage [n (%)] | 0.440a | ||
| 0–I | 22 (31.0) | 12 (24.0) | |
| II | 27 (38.0) | 17 (34.0) | |
| III | 22 (31.0) | 21 (42.0) | |
| Lymph nodes harvested [M (range)] | 14 (2–45) | 16 (3–42) | 0.011b |
| Positive positive lymph node ratio [M (range)] | 0 (0–0.11) | 0 (0–0.11) | 0.895b |
| Histopathology [n (%)] | 0.708a | ||
| Adenocarcinoma | 64 (90.1) | 44 (88.0) | |
| Mucinous/signet–ring cell | 7 (9.9) | 6 (12.0) | |
| Adenocarcinoma differentiation [n (%)] | 0.315a | ||
| Well and moderate | 59 (92.2) | 37 (84.1) | |
| Poor | 5 (7.8) | 7 (15.9) | |
| Lymphovascular invasion [n (%)] | 0.964a | ||
| Yes | 23 (32.4) | 16 (32.0) | |
| No | 48 (67.6) | 34 (68.0) | |
| Nerve invasion [n (%)] | 0.177a | ||
| Yes | 15 (21.1) | 16 (32.0) | |
| No | 56 (78.9) | 34 (68.0) | |
| Positive CRM [n (%)] | 5 (7.0) | 10 (22.0) | 0.033a |
| Incidence of R0 resection [n (%)] | 66 (93.0) | 40 (80.0) | 0.033a |
ELAPE extralevator abdominoperineal excision, APE abdominoperineal excision, CRM circumferential resection margin. aChi-square test, bMann-Whitney U test